PDS Biotech Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤PIPE financing up to $22.3 million led by Nant Capital, with initial closing completed
- ➤Cash and equivalents $15.2 million as of September 30, 2026
- ➤Q3 net loss $7.6 million, or $0.11 per share, versus $9.0 million
- ➤Q3 operating expenses $5.9 million, down from $8.1 million year over year
- ➤NantWorks receives one-year exclusive right to negotiate PDS0101 license
Expert Statements
Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech
“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program”
Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech
“We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”
Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech
“We are pleased to have the support of Dr. Soon-Shiong and NantWorks, who share our belief in the promise of our immunotherapy platforms and led our PIPE financing of up to $22.3 million, the initial closing of which we completed this quarter.”
PRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended September 30, 2026.
“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated. We are pleased to have the support of Dr. Soon-Shiong and NantWorks, who share our belief in the promise of our immunotherapy platforms and led our PIPE financing of up to $22.3 million, the initial closing of which we completed this quarter.”
Get started
Create a free account to read the full story.